The first patient enrolled in a similar study at the University of Pennsylvania, who had 11 prior lines of therapy and whose myeloma cells expressed BCMA, had a CR within 4 weeks of treatment, with a negative bone marrow biopsy, and response is ongoing at 15-plus months. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.